Seeking Alpha

Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share...

Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share acquisition of Obagi Medical (OMPI). The deal now needs the authorization of the Antimonopoly Committee of Ukraine. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs